Protagonist Therapeutics Stock Probability of Future Stock Price Finishing Over 25.70

PTGX Stock  USD 25.70  1.15  4.28%   
Protagonist Therapeutics' implied volatility is one of the determining factors in the pricing options written on Protagonist Therapeutics. Implied volatility approximates the future value of Protagonist Therapeutics based on the option's current value. Options with high implied volatility have higher premiums and can be used to hedge the downside of investing in Protagonist Therapeutics over a specific time period. For example, 2024-05-17 CALL at $25.0 is a CALL option contract on Protagonist Therapeutics' common stock with a strick price of 25.0 expiring on 2024-05-17. The contract was last traded for $3.25 and, as of today, has 23 days remaining before the expiration. The option is currently trading at a bid price of $1.3, and an ask price of $4.9. The implied volatility as of the 25th of April is 82.98. View All Protagonist options

Closest to current price Protagonist long CALL Option Payoff at Expiration

Protagonist Therapeutics' future price is the expected price of Protagonist Therapeutics instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Protagonist Therapeutics performance during a given time horizon utilizing its historical volatility. Check out Protagonist Therapeutics Backtesting, Protagonist Therapeutics Valuation, Protagonist Therapeutics Correlation, Protagonist Therapeutics Hype Analysis, Protagonist Therapeutics Volatility, Protagonist Therapeutics History as well as Protagonist Therapeutics Performance.
For more information on how to buy Protagonist Stock please use our How to Invest in Protagonist Therapeutics guide.
  
At this time, Protagonist Therapeutics' Price Book Value Ratio is fairly stable compared to the past year. Price Earnings To Growth Ratio is likely to rise to 0.39 in 2024, whereas Price To Sales Ratio is likely to drop 20.61 in 2024. Please specify Protagonist Therapeutics' target price for which you would like Protagonist Therapeutics odds to be computed.

Protagonist Therapeutics Target Price Odds to finish over 25.70

The tendency of Protagonist Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 25.70 90 days 25.70 
about 86.44
Based on a normal probability distribution, the odds of Protagonist Therapeutics to move above the current price in 90 days from now is about 86.44 (This Protagonist Therapeutics probability density function shows the probability of Protagonist Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 2.88 indicating as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Protagonist Therapeutics will likely underperform. Additionally Protagonist Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
   Protagonist Therapeutics Price Density   
       Price  

Predictive Modules for Protagonist Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Protagonist Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Protagonist Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
22.3825.6528.92
Details
Intrinsic
Valuation
LowRealHigh
23.1329.8233.09
Details
Naive
Forecast
LowNextHigh
21.7224.9928.26
Details
6 Analysts
Consensus
LowTargetHigh
37.0840.7545.23
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Protagonist Therapeutics. Your research has to be compared to or analyzed against Protagonist Therapeutics' peers to derive any actionable benefits. When done correctly, Protagonist Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Protagonist Therapeutics.

Protagonist Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Protagonist Therapeutics is not an exception. The market had few large corrections towards the Protagonist Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Protagonist Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Protagonist Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over NYSE Composite
-0.09
β
Beta against NYSE Composite2.88
σ
Overall volatility
1.89
Ir
Information ratio 0.02

Protagonist Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Protagonist Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Protagonist Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Protagonist Therapeutics had very high historical volatility over the last 90 days
The company reported the previous year's revenue of 60 M. Net Loss for the year was (78.95 M) with profit before overhead, payroll, taxes, and interest of 26.58 M.
Protagonist Therapeutics currently holds about 291.89 M in cash with (70.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.95.
Protagonist Therapeutics has a frail financial position based on the latest SEC disclosures
Over 98.0% of the company shares are owned by institutional investors
Latest headline from MacroaxisInsider: Disposition of 1234 shares by Asif Ali of Protagonist Therapeutics at 25.11 subject to Rule 16b-3

Protagonist Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Protagonist Stock often depends not only on the future outlook of the current and potential Protagonist Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Protagonist Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding56.8 M
Cash And Short Term Investments341.6 M

Protagonist Therapeutics Technical Analysis

Protagonist Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Protagonist Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Protagonist Therapeutics. In general, you should focus on analyzing Protagonist Stock price patterns and their correlations with different microeconomic environments and drivers.

Protagonist Therapeutics Predictive Forecast Models

Protagonist Therapeutics' time-series forecasting models is one of many Protagonist Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Protagonist Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Protagonist Therapeutics

Checking the ongoing alerts about Protagonist Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Protagonist Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Protagonist Therapeutics had very high historical volatility over the last 90 days
The company reported the previous year's revenue of 60 M. Net Loss for the year was (78.95 M) with profit before overhead, payroll, taxes, and interest of 26.58 M.
Protagonist Therapeutics currently holds about 291.89 M in cash with (70.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.95.
Protagonist Therapeutics has a frail financial position based on the latest SEC disclosures
Over 98.0% of the company shares are owned by institutional investors
Latest headline from MacroaxisInsider: Disposition of 1234 shares by Asif Ali of Protagonist Therapeutics at 25.11 subject to Rule 16b-3
When determining whether Protagonist Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Protagonist Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Protagonist Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Protagonist Therapeutics Stock:
Check out Protagonist Therapeutics Backtesting, Protagonist Therapeutics Valuation, Protagonist Therapeutics Correlation, Protagonist Therapeutics Hype Analysis, Protagonist Therapeutics Volatility, Protagonist Therapeutics History as well as Protagonist Therapeutics Performance.
For more information on how to buy Protagonist Stock please use our How to Invest in Protagonist Therapeutics guide.
Note that the Protagonist Therapeutics information on this page should be used as a complementary analysis to other Protagonist Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.

Complementary Tools for Protagonist Stock analysis

When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Money Managers
Screen money managers from public funds and ETFs managed around the world
Is Protagonist Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protagonist Therapeutics. If investors know Protagonist will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protagonist Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.39)
Revenue Per Share
1.057
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.19)
Return On Equity
(0.29)
The market value of Protagonist Therapeutics is measured differently than its book value, which is the value of Protagonist that is recorded on the company's balance sheet. Investors also form their own opinion of Protagonist Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protagonist Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protagonist Therapeutics' market value can be influenced by many factors that don't directly affect Protagonist Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protagonist Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protagonist Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protagonist Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.